A New Dual-Targeted ADC Shows Promise in Resistant EGFR-Mutant Lung Cancer
A pooled analysis of phase 1 and 2 trials reveals encouraging data for izalontamab brengitecan (BL-B01D1), a first-in-class bispecific antibody-drug conjugate targeting both EGFR and HER3. The drug was evaluated in patients with EGFR-mutated non-small cell lung cancer who had progressed on tyrosine kinase inhibitors, a population with limited therapeutic options. This novel approach aims to overcome resistance mechanisms by delivering a cytotoxic payload directly to tumor cells expressing these two key receptors, demonstrating preclinical and early clinical activity that could expand the precision oncology arsenal.
Why it might matter to you: This development directly addresses a critical unmet need in targeted therapy for lung cancer, offering a potential new line of attack against drug resistance. For oncologists, it represents a novel mechanism—a bispecific ADC—that could inform future combination strategies and treatment sequencing. Its progress underscores the ongoing evolution of antibody-drug conjugates beyond single targets, potentially improving outcomes for patients with driver mutations.
Source →
Glucocorticoids and Checkpoint Inhibitors: A Reassuring Coexistence in RA and Cancer
A real-world study of Medicare patients with rheumatoid arthritis and metastatic non-small cell lung cancer treated with immune checkpoint inhibitors (ICIs) found that glucocorticoid use was not associated with worse survival. The analysis, which excluded dexamethasone users in its primary model, focused on glucocorticoid exposure within 91 days of ICI initiation. This finding challenges a common clinical concern that immunosuppressive steroids might attenuate the efficacy of immunotherapy, providing evidence that managing autoimmune conditions with typical glucocorticoid doses may be compatible with ICI cancer therapy.
Why it might matter to you: This data offers practical guidance for oncologists managing the complex interplay between cancer immunotherapy and autoimmune comorbidities. It suggests that the concurrent use of glucocorticoids for rheumatoid arthritis does not necessarily compromise ICI outcomes, which can inform more confident treatment decisions in this patient population. This helps refine the risk-benefit calculus in immuno-oncology, moving beyond blanket concerns to more nuanced, evidence-based management.
Source →
Homologous Recombination Deficiency: A Key to Platinum Response in Pancreatic Cancer?
A narrative review synthesizes the growing evidence on the implications of homologous recombination deficiency (HRD) for neoadjuvant platinum-based chemotherapy in pancreatic cancer. The article discusses how genomic instability caused by HRD, often due to mutations in genes like BRCA, may render tumors more susceptible to DNA-damaging agents such as platinum drugs. This framework positions HRD as a potential predictive biomarker that could help stratify patients for more personalized, effective neoadjuvant treatment strategies in a disease known for its aggressive biology and limited options.
Why it might matter to you: This review highlights a pathway for bringing precision oncology to pancreatic cancer treatment, a field in urgent need of better biomarkers. For clinicians and researchers, it underscores the importance of comprehensive genomic profiling to identify HRD, which could optimize patient selection for platinum-based regimens and improve surgical outcomes. It connects fundamental cancer biology—DNA repair defects—to a direct clinical application in treatment sequencing and trial design.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.